Home

Instant Insights / Your 2019 Outlook: Trends, Predictions, Challenges

Expert Opinion

Quick take: Key themes affecting pharma in 2019

Here are a few areas I’ll be keeping an eye on in the pharmacy industry next year.

By Max Nisen | December 31, 2018 at 10:28 AM

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

For the biopharma industry, 2018 was a year marked by generally robust profits and a handful of superlatives. These include Takeda Pharmaceutical Co.’s $62 billion bid for Shire Plc — the biggest announced drug deal in more than a decade — as well as a record number of approvals of new and generic medicines by the U.S. Food and Drug Administration and the most aggressive drug-pricing proposal to ever emerge from a Republican administration.

No promises on another megadeal in 2019, but I can guarantee that drug pricing will still be a thing. Here are a few areas I’ll be keeping an eye on:

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account? Sign In Now

Dig Deeper

BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Exclusive discounts on BenefitsPRO.com and ALM events.